Jubilant Pharmova Limited JUBLPHARMA NIFTY_SMALLNSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India

https://www.jubilantpharmova.com

Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research Development and Manufacturing Organisation; and Proprietary Novel Drugs. The Radiopharma segment offers radiopharmaceuticals products, which are used in the diagnosis and treatment of various diseases, including pulmonary embolism, cancer, coronary artery disease, and others. Its Allergy Immunotherapy segment provides specialised diagnostic devices for skin testing, as well as venom and allergy immunotherapy products. The Contract Development and Manufacturing Organisation - Sterile Injectables segment offers contract manufacturing services for sterile fill and finish injectables, liquids, ointments, creams, and ampoules. Its Generics segment engages in the development, manufacturing, distribution, sale, and marketing of generic formulations for therapeutic areas comprising cardiovascular system, central nervous system, gastrointestinal, antibiotics, and multispecialty. The Contract Research Development and Manufacturing Organisation segment offers drug discovery services and active pharmaceutical ingredients. The Proprietary Novel Drugs segment provides patient-focused biopharmaceutical services to address unmet medical needs in oncology and autoimmune diseases. The company serves pharmaceutical, biotech, group purchasing organisations, allergists, and hospitals sectors. It sells its products through a network of dealers and distributors. The company was formerly known as Jubilant Life Sciences Limited and changed its name to Jubilant Pharmova Limited in February 2021. The company was incorporated in 1978 and is based in Noida, India.

Market & Price

Market Cap

₹15,759.52 Cr

Current Price

₹995.00

High / Low (52W)

₹1,236.30 / ₹807.65

Beta

0.51

Valuation

Stock P/E

39.69

Industry PE

37.60

Forward P/E

19.59

PEG Ratio

0.14

Book Value

₹415.87

Price to Book

2.39

P/S

1.90

EV/EBITDA

14.36

Dividend Yield

0.50%

Profitability & Returns

ROCE

6.36%

ROE

5.96%

ROA

3.62%

Profit Margin

4.81%

Op Margin

9.72%

EPS (Latest Qtr)

₹7.52

EPS (TTM)

₹25.07

Balance Sheet & Liquidity

Debt/Equity

0.51

Quick Ratio

0.95

Current Ratio

1.62

Debt

₹3,614.70 Cr

Total Assets

₹15,522.70 Cr

Current Assets

₹4,109.30 Cr

Working Capital

₹1,570.40 Cr

Ownership

Promoter Holding

57.95%

Chg in Prom Hold

FII / Inst Holding

21.41%

Chg in FII Hold

Financial Snapshot

Enterprise Value

₹18,085.40 Cr

Total Revenue (TTM)

₹8,279.60 Cr

EBITDA

₹1,259.80 Cr

Free Cash Flow

₹-568.25 Cr

Operating Cash Flow

₹1,226.80 Cr

Shares Outstanding

₹15.84 Cr

Gross Margin

68.06%

Payout Ratio

19.94%

Growth (CAGR)

Revenue 5Y

9.77%

Profit 5Y

251.09%

Revenue (YoY)

18.70%

Earnings (YoY)

-22.40%

PROS

Profit CAGR of 251.1% over 5 years.

CONS

In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP ₹	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	JUBLPHARMA Jubilant Pharmova Limited NIFTY_SMALLNSEPHARMA	995.00	39.69	₹15,759.52 Cr	0.50%	6.36%	5.96%	9.77%	251.09%
2	SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA	1,799.20	37.59	₹4.32 L Cr	0.92%	17.94%	14.72%	10.39%	10.65%
3	DIVISLAB Divi's Laboratories Limited NSEPHARMA	6,667.00	68.97	₹1.77 L Cr	0.45%	18.96%	16.19%	11.27%	12.08%
4	TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA	4,410.80	68.96	₹1.49 L Cr	0.86%	9.06%	16.98%	13.27%	20.21%
5	CIPLA Cipla Limited NIFTY50NSEAIPHARMA	1,401.00	29.16	₹1.13 L Cr	0.93%	14.88%	11.74%	7.23%	11.45%
6	DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA	1,303.50	25.90	₹1.09 L Cr	0.61%	14.00%	11.83%	10.96%	-2.35%
7	ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA	1,077.70	21.51	₹1.08 L Cr	0.09%	19.24%	18.32%	16.55%	36.99%
8	LUPIN Lupin Limited NIFTY_MIDNSEPHARMA	2,267.70	19.49	₹1.04 L Cr	0.53%	28.42%	26.91%	19.10%	131.46%
9	MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA	2,375.60	51.29	₹98,090.71 Cr	0.08%	13.78%	12.45%	17.73%	14.28%

Quarterly Results

Figures in INR.

Metric	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Dec 2025	Mar 2026
Revenue	1,742.20 Cr	1,813.70 Cr	1,915.80 Cr	1,878.90 Cr	2,116.10 Cr	2,272.20 Cr
Cost of Revenue	554.80 Cr	574.40 Cr	626.10 Cr	618.20 Cr	716.30 Cr	713.30 Cr
Gross Profit	1,187.40 Cr	1,239.30 Cr	1,289.70 Cr	1,260.70 Cr	1,399.80 Cr	1,558.90 Cr
Operating Expenses	989.40 Cr	1,043.20 Cr	1,039.50 Cr	1,069.20 Cr	1,231.00 Cr	1,336.40 Cr
Operating Income	198.00 Cr	196.10 Cr	250.20 Cr	191.50 Cr	168.80 Cr	222.50 Cr
EBITDA	296.80 Cr	277.40 Cr	353.90 Cr	301.50 Cr	270.20 Cr	349.30 Cr
Interest Expense	61.00 Cr	55.60 Cr	52.70 Cr	49.00 Cr	56.10 Cr	56.50 Cr
Pretax Income	144.40 Cr	130.50 Cr	206.00 Cr	154.40 Cr	93.40 Cr	176.00 Cr
Tax Provision	41.90 Cr	29.80 Cr	54.70 Cr	51.90 Cr	37.60 Cr	56.70 Cr
Net Income	102.80 Cr	100.90 Cr	153.60 Cr	102.90 Cr	55.90 Cr	119.40 Cr
Diluted EPS	6.46	6.36	9.68	6.47	3.52	7.52

Profit & Loss (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Revenue	-	6,219.30 Cr	6,644.80 Cr	7,192.10 Cr	8,225.00 Cr
Cost of Revenue	-	2,222.80 Cr	2,422.10 Cr	2,317.00 Cr	2,644.30 Cr
Gross Profit	-	3,996.50 Cr	4,222.70 Cr	4,875.10 Cr	5,580.70 Cr
Operating Expenses	-	3,766.60 Cr	3,699.60 Cr	4,070.00 Cr	4,761.30 Cr
Operating Income	-	229.90 Cr	523.10 Cr	805.10 Cr	819.40 Cr
EBITDA	-	750.40 Cr	808.80 Cr	1,589.50 Cr	1,266.30 Cr
Interest Expense	-	168.60 Cr	256.40 Cr	240.30 Cr	211.80 Cr
Pretax Income	-	27.80 Cr	170.50 Cr	980.60 Cr	614.10 Cr
Tax Provision	-	92.70 Cr	97.80 Cr	144.30 Cr	216.60 Cr
Net Income	-	-61.00 Cr	77.10 Cr	839.40 Cr	398.50 Cr
Diluted EPS	26.00	-3.83	4.86	52.85	-

Compounded Sales Growth

5 Years:	9.77%
1 Year:	18.70%

Compounded Profit Growth

5 Years:	251.09%
1 Year:	-22.40%

Stock Price Performance

1 Year:	-13.48%
6 Months:	-5.94%
3 Months:	+14.03%
1 Month:	+5.58%

Balance Sheet (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Total Assets	-	11,156.70 Cr	11,548.50 Cr	12,756.40 Cr	15,522.70 Cr
Current Assets	-	3,762.40 Cr	3,876.10 Cr	3,577.20 Cr	4,109.30 Cr
Cash & Equivalents	-	1,010.80 Cr	953.90 Cr	1,086.20 Cr	1,267.10 Cr
Inventory	-	1,380.50 Cr	1,289.60 Cr	1,129.20 Cr	1,231.50 Cr
Receivables	-	961.20 Cr	915.90 Cr	891.50 Cr	1,069.60 Cr
Total Liabilities	-	5,764.90 Cr	6,127.40 Cr	6,517.80 Cr	8,427.10 Cr
Current Liabilities	-	1,772.40 Cr	1,889.00 Cr	2,164.60 Cr	2,538.90 Cr
Long Term Debt	-	3,110.40 Cr	3,167.10 Cr	2,150.30 Cr	2,971.70 Cr
Total Debt	-	3,676.80 Cr	3,664.00 Cr	2,731.00 Cr	3,614.70 Cr
Total Equity	-	5,399.30 Cr	5,433.90 Cr	6,254.90 Cr	7,092.80 Cr
Shares Outstanding	-	15.93 Cr	15.93 Cr	15.93 Cr	15.93 Cr

Cash Flows (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Operating Cash Flow	-	660.70 Cr	971.30 Cr	1,072.10 Cr	1,226.80 Cr
Investing Cash Flow	-	-544.40 Cr	-607.90 Cr	487.70 Cr	-1,260.00 Cr
Financing Cash Flow	-	-156.70 Cr	-432.50 Cr	-1,452.70 Cr	94.90 Cr
Capital Expenditure	-	-814.50 Cr	-897.70 Cr	-1,115.60 Cr	-1,449.10 Cr
Free Cash Flow	-	-153.80 Cr	73.60 Cr	-43.50 Cr	-222.30 Cr
Net Change in Cash	-	-40.40 Cr	-69.10 Cr	107.10 Cr	61.70 Cr

Ratios (Annual)

Figures in %.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Gross Margin %	-	64.3%	63.5%	67.8%	67.9%
Operating Margin %	-	3.7%	7.9%	11.2%	10.0%
Net Margin %	-	-1.0%	1.2%	11.7%	4.8%
ROE %	-	-1.1%	1.4%	13.4%	5.6%
ROCE %	-	2.4%	5.4%	7.6%	6.3%

Shareholding Pattern

Insiders

57.95%

Institutions

21.41%

Public Float

50.91%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for JUBLPHARMA

No recent headlines available.

JUBLPHARMA · Healthcare